Investor Presentation Q1 2023

39 Investor presentation First three months of 2023 Novo Nordisk has a leadership position within the growing diabetes market Global diabetes market by treatment class¹ Novo Nordisk remains global diabetes value market leader DKK billion Market CAGR: 10% 40% 500 400 30% Novo Nordisk market share and share of growth 60% 32% 40% Novo NordiskⓇ 38% 36% 300 CAGR: -3% 20% CAGR: 33% 200 CAGR: -4% 20% 32% 29% 10% 100 CAGR: 29% 0 0% 0% 2018 2019 2020 2021 2022 Feb Feb Feb Feb 2013 2023 2020 2023 GLP-1 Insulin SGLT-2i DPP-4i Novo Nordisk -Takeda -NN market share Sanofi -Merck Eli Lilly -NN share of growth BI Astra Zeneca -J&J 1 Data is based on company reported sales from Sanofi, Eli Lilly, AstraZeneca, GSK, Novartis, Johnson & Johnson, and Merck. Data does not include generic metformin, sulphonylureas or thiazolidinedione BI: Boehringer Ingelheim; J&J: Johnson & Johnson; NN: Novo Nordisk Source: IQVIA MAT, Feb 2023 value figures Note: IQVIA data can be inflated due to use of list prices in the US Market growth (right axis) -NN growth (right axis) Novartis

View entire presentation